Item 1.01 Entry into a Material Definitive Agreement.

On July 29, 2022, Adhera Therapeutics, Inc. (the "Company") and Melior Pharmaceuticals I, LLC ("Melior") entered into the Second Addendum to the License Agreement (the "Second Addendum"). The License Agreement (the "Agreement"), dated August 24, 2021, granted the Company an exclusive license for the development and commercialization of Melior's MLR-1023. The MLR-1023 license was scheduled to terminate due to the inability to meet certain milestones in the Agreement. In accordance with the Second Addendum and subject to the terms and conditions therein, the MLR-1023 license was extended until February 2023.

The material obligations of the Company under the Second Addendum include:





  ? license payment of approximately $137,000 by the Company to Melior (this
    payment was made on July 29, 2022);
  ? maintaining the full-time employment of its Chief Scientific Officer; and
  ? raising $500,000 in working capital.

The foregoing summary of the material terms of the form of the Second Addendum is not complete and is qualified in its entirety by reference to the full text thereof, a copy of which is filed herewith as Exhibit 10.1, and incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.





Exhibit No.   Description

10.1            Second Addendum to the License Agreement
104           Cover Page Interactive Data File (embedded within the Inline XBRL
              document)

© Edgar Online, source Glimpses